These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33718115)

  • 1. PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation.
    Pacheco-Torres J; Penet MF; Krishnamachary B; Mironchik Y; Chen Z; Bhujwalla ZM
    Front Oncol; 2020; 10():614365. PubMed ID: 33718115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation.
    Chen Z; Krishnamachary B; Penet MF; Bhujwalla ZM
    Theranostics; 2018; 8(1):1-12. PubMed ID: 29290789
    [No Abstract]   [Full Text] [Related]  

  • 3. VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation.
    Tan S; Chen Z; Mironchik Y; Mori N; Penet MF; Si G; Krishnamachary B; Bhujwalla ZM
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
    Lee CK; Atibalentja DF; Yao LE; Park J; Kuruvilla S; Felsher DW
    Nanotheranostics; 2022; 6(3):243-255. PubMed ID: 35145835
    [No Abstract]   [Full Text] [Related]  

  • 5. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
    Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
    Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer.
    Chen Z; Krishnamachary B; Mironchik Y; Ray Banerjee S; Pomper MG; Bhujwalla ZM
    Nanoscale; 2022 Oct; 14(38):14014-14022. PubMed ID: 36093754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
    Xu S; Cui F; Huang D; Zhang D; Zhu A; Sun X; Cao Y; Ding S; Wang Y; Gao E; Zhang F
    Int J Nanomedicine; 2019; 14():17-32. PubMed ID: 30587982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells.
    Camorani S; Tortorella S; Agnello L; Spanu C; d'Argenio A; Nilo R; Zannetti A; Locatelli E; Fedele M; Comes Franchini M; Cerchia L
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
    Luo X; Peng X; Hou J; Wu S; Shen J; Wang L
    Int J Nanomedicine; 2017; 12():5331-5343. PubMed ID: 28794626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
    Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
    Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer.
    Liu B; Cao W; Qiao G; Yao S; Pan S; Wang L; Yue C; Ma L; Liu Y; Cui D
    Acta Biomater; 2019 Nov; 99():307-319. PubMed ID: 31513911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
    Wen J; Qiu N; Zhu Z; Bai P; Hu M; Qi W; Liu Y; Wei A; Chen L
    Drug Deliv; 2021 Dec; 28(1):1055-1066. PubMed ID: 34078185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
    Kwak SY; Lee S; Han HD; Chang S; Kim KP; Ahn HJ
    Mol Pharm; 2019 Dec; 16(12):4940-4953. PubMed ID: 31651174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
    He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
    Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells].
    Sun B; Li X; Zheng G; Dong T; Li Y; Li H; Yan Y; Bai J; Xu S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Jan; 31(1):37-43. PubMed ID: 30707867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer.
    Linde C; Chien YT; Chen Z; Mu Q
    Front Oncol; 2024; 14():1393492. PubMed ID: 38756653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.